Welcome to Outsourced Pharma Live – An online interactive forum to discuss the most important topics and trends impacting drug development and manufacturing outsourcing, and working with CDMOs.
Throughout the year, our Chief Editor, Louis Garguilo, brings together industry experts to discuss how sponsor companies can tackle some of today's biggest challenges in managing your CDMOs. Our audience gets to ask and have answered their questions during the presentation. Each Outsourced Pharma Live session is archived, and can be accessed at any time by registered site users.
BIOLOGICS DEVELOPMENT AT CDMOS DEMANDS MORE FLEXIBILITY
Biologics Development At CDMOs Demands More Flexibility
Outsourced Pharma Live explored the specific challenges of biologics development that are pushing CDMOs to adopt more flexible approaches. The discussion covered key factors such as customized manufacturing solutions, adaptive project timelines, and responsive te...
OUTSOURCED PHARMA LIVE - 2026 EVENT SCHEDULE
Feb. 5: The Unfiltered Truth About CDMO Selection (On-Demand)
Mar. 17: Clinical Supply Chain Therapy: Lowering Risk (And Your Blood Pressure) (On Demand)
Apr. 22: One Program, Many CDMOs: Managing Multi-Partner Strategies
Jun. 6: Models For Derisking Tech Transfer To CDMOs
Aug. 4: A Discussion On The Direct Pathway from Academia To CDMOs
Oct. 1: Quality & Compliance in CDMO Relationships: Oversight And Trust
Nov. 11: Outsourcing the Uncharted: Manufacturing CRISPR, Microbiome, and Neoantigen Therapies
Dec. 2: AI, Digital Twins, and Data-Driven CDMO Partnerships
MEET OUR MODERATOR
Jeff Buguliskis is deputy chief editor of Outsourced Pharma, where he translates complex biology and manufacturing into practical guidance for drug sponsors navigating CDMO selection, tech transfer, analytics, and timelines. He holds a PhD in Molecular Cell Biology from Thomas Jefferson University and a BS in Biology from the University of the Sciences in Philadelphia. His editorials reflect two decades spanning bench science, publishing, and industry, and are written to help readers see both the big-picture dynamics and on-the-ground realities of outsourcing.
Prior to Outsourced Pharma, Buguliskis served as a technical editor at Genetic Engineering & Biotechnology News (GEN), where he authored features and hosted GEN’s “GenCast” podcast series and managed multimedia initiatives at Mary Ann Liebert Publishing. Afterwards, Jeff engaged audiences with his editorial leadership as Director of Content at SynBioBeta. Earlier in his career, he conducted postdoctoral research in molecular microbiology at Washington University in St. Louis, publishing on parasite invasion mechanisms—including a widely cited Toxoplasma gondii study on the rhomboid protease ROM4. These experiences inform his science-minded, operations-aware voice across the outsourcing lifecycle.
Jeff is an avid Philly sports fan, homebrewer, and foodie.
THE "TIDES" HAVE CHANGED: OUTSOURCING OLIGOS AND PEPTIDES
The "Tides" Have Changed: Outsourcing Oligos And Peptides
Shifting demand for oligos and peptides drove innovation in CDMO partnerships and reshaped outsourcing relationships. In this Outsourced Pharma Live panel, industry experts shared best practices for outsourcing these specialized therapeutics, with a focus on capacity, reg...
SELECTING & MANAGING CDMOS FOR NOVEL THERAPIES
Selecting & Managing CDMOs For Novel Therapies
Outsourced Pharma Live welcomes Verve Therapeutics' Praveen Prasanna, Ph.D., GenSight Biologics' Scott Jeffers, and University of Minnesota's Vaibhav Patel to explore the critical considerations and best practices for selecting and managi...
EMERGING MODELS FOR OUTSOURCING DEVELOPMENT AND MANUFACTURING
Emerging Models for Outsourcing Development and Manufacturing
What's your development and manufacturing outsourcing strategy based on? Do you have the right contracts and external relationships in place to successfully implement that strategy? Are there new models for sponsor-CDMO partnerships?
HOW CAN CMC KEEP UP WITH THE RUSH TO THE CLINIC?
How Can CMC Keep Up With The Rush To The Clinic?
In an effort to support fast-track clinical programs and the otherwise rush to the clinic, CMC (chemistry, manufacturing, and controls) professionals in early-stage biotechs find themselves behind the eight ball. Start-ups habitually overestimate their understanding of th...
A NEW AGE FOR SMALL MOLECULE DEVELOPMENT
A New Age For Small Molecule Development
Expedited regulatory pathways are being used more often, even as small molecule pipeline candidates grow in complexity, creating new risks for drug developers. The need for speed – from discovery to development to manufacturing at scale – while maintaining tig...
EFFECTIVELY OUTSOURCING DRUG DEVELOPMENT IN 2024
Effectively Outsourcing Drug Development in 2024
Has 2024 ushered in new trends, challenges, and opportunities for outsourcing drug and therapy development, and working with external partners? Our panel of development experts thinks so. From new platforms, modalities and technologies, to the fundamentals of process deve...
CAUTION: OUTSOURCING WITHOUT CONSULTANTS COULD BE HAZARDOUS
When Consultants Work Out, And When They Don't
Speaking from experience as an executive at both pharma sponsors and CDMOs, Kurt Neilsen says consultants play a vital role … until they don’t.
WHAT'S DRIVING THE CELL & GENE THERAPY OUTSOURCING CAPACITY CYCLE?
What's Driving The Cell & Gene Therapy Outsourcing Capacity Cycle?
The feared, then realized capacity shortage in the cell & gene outsourcing space appears to be abating. But the market – and economy – remain in flux. We could be heading for overcapacity for some services, but remain constricted in others.
In Oc...